Biotechnology T-cell therapy company Adaptimmune Therapeutics saw its shares close up 200% at $3.99 on Monday, having rocketed nearly 300%, on encouraging research results and the news that it has entered into a co-development and co-commercialization agreement with Japanese pharma major Astellas Pharma to bring new stem-cell derived allogeneic T-cell therapies to people with cancer that could be worth nearly $900 million. 14 January 2020